Scientific Advisory Board
ADAM J. BASS, MD, COLUMBIA UNIVERSITY MEDICAL CENTER, IRVING PROFESSOR OF MEDICINE AND DIRECTOR OF THE CENTER FOR PRECISION CANCER MEDICINE
Adam J. Bass, MD, is a physician-scientist whose lab investigates the genomics and biology of gastroesophageal cancer. Dr. Bass is a Professor of Medicine at Columbia University Medical Center.
Andrew T. Chan, MD, MPH, Harvard T.H. Chan School of Public Health and Massachusetts General Hospital
Andrew T. Chan, MD, MPH, is a Professor of Medicine at Harvard Medical School (HMS), Professor of Immunology and Infectious Diseases at the Harvard T.H. Chan School of Public Health, Chief of the Clinical and Translational Epidemiology Unit at Massachusetts General Hospital (MGH), and the Director of Epidemiology at the MGH Cancer Center. Dr. Chan is a gastroenterologist and a leading investigator in cancer prevention, supported as an Outstanding Investigator of the National Cancer Institute and Team Leader for the Stand Up to Cancer Gastric Cancer Interception Team.
Carlos U. Corvera, MD, FACS, UCSF, Helen Diller Family Comprehensive Cancer Center
Carlos Corvera, MD, is Professor of Surgery and Chief of Hepatobiliary and Pancreas Surgery at UCSF. A trained surgical oncologist, Dr. Corvera has extensive experience in the treatment of benign and malignant hepatobiliary disease including hepatocellular carcinoma (primary liver cancer), liver metastases, and cancers of the stomach, gallbladder, bile ducts, and pancreas. Dr. Corvera is a panel member on the NCCN esophageal and gastric cancer guidelines since 2017. Dr. Corvera is the past President of the UCSF Naffziger Surgical Society (2013-2014), the alumni society for the UCSF Department of Surgery dedicated to surgical excellence.
Pamela L. Kunz, MD, Yale School of Medicine, Yale Cancer Center, and Smilow Cancer Hospital
Pamela L. Kunz, MD, is an Associate Professor of Medicine (Oncology) at the Yale School of Medicine, a GI medical oncologist, and Leader of the GI Cancer Program at Yale Cancer Center and Smilow Cancer Hospital. She specializes in the treatment of patients with gastrointestinal malignancies and has developed broad investigative programs in this field encompassing clinical trials, health services research, and translational science.
Uri Ladabaum, MD, MS, Stanford University School of Medicine
Uri Ladabaum, MD, MS, is a Professor of Medicine, Senior Vice Chief Director, Gastrointestinal Cancer Prevention Program, Division of Gastroenterology and Hepatology at Stanford University School of Medicine. Dr. Ladabaum’s clinical and research focus is gastrointestinal risk management and prevention, including early detection. His interests include ensuring the proper care of patients with elevated cancer risk, as well as instituting effective screening approaches for populations at average risk of cancer.
R. Jacob Vogelstein, PhD, Catalio Capital Management
R. Jacob Vogelstein, PhD, is a Co-Founder and Managing Partner of Catalio Capital Management, where he conceives, creates, and capitalizes breakthrough biomedical technology companies founded by world-renowned scientist-entrepreneurs.
Our work is inspired by Sara Schottenstein, a wife, mother, and attorney who lived life with warmth and authenticity.
Gastric cancer, also known as stomach cancer, is the third leading cause of cancer deaths, with over 1 million patients diagnosed per year worldwide.